Sonire Therapeutics started a U.S.-based Sunrise II study of Suizenji, its ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors. The company initiated the study after closing an $18 million Series A financing round on April 15, positioning the program to generate U.S. clinical evidence for a platform that aims to deliver precise tissue destruction. The trial is focused on the Sunrise II evaluation of the device in a clinical setting, advancing the company from early development into a pathway that may support future regulatory conversations. For medtech and translational oncology, the launch adds another image-guided ablation option aimed at improving local control in pancreatic cancer, where durable outcomes remain challenging.